Finance

Lists
Why is XGN down 6.35%?
Dive Deeper
XGN:NASDAQ
Exagen Inc
$4.13
-6.35%
(-0.28) 1D
Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for XGN...
Open
$4.37
High
$4.38
Low
$3.84
Mkt. cap
105.37M
Avg. vol.
511.56K
Volume
3.36M
52-wk high
$9.28
52-wk low
$2.60
EPS
-$0.75
Beta
2.25
Shares outstanding
25.51M
No. of employees
218
Open
$4.37
High
$4.38
Low
$3.84
Mkt. cap
105.37M
Avg. vol.
511.56K
Volume
3.36M
52-wk high
$9.28
52-wk low
$2.60
EPS
-$0.75
Beta
2.25
Shares outstanding
25.51M
No. of employees
218
News stories
From web sources and news partners
About Exagen Inc
CEO-
Employees218
Founded2002
HeadquartersVista, California, United States
SectorHealth Care
IndustryBiotechnology
Websiteexagen.com
Analyst ratings
Based on 5 analysts giving stock ratings to XGN in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for XGN in the last 3 months.
Highest
Current $4.13
$12.00 (+190.56%)
Average
$10.00 (+142.13%)
Lowest
$9.00 (+117.92%)
Analyst
Recommendation
Action
Price target
Projected
Date
Max Masucci
Roth MKM
Buy
Maintained
$9.00
+117.9%
11/11/2026
Mark Massaro
BTIG
Buy
Reiterated
$9.00
+117.9%
11/10/2026
Kyle Mikson CFA
Canaccord Genuity
Buy
Reiterated
$9.00
+117.9%
11/11/2026
Mayank Mamtani
B. Riley Securities
Buy
Reiterated
$12.00
+190.6%
11/02/2026
Daniel Brennan
TD Cowen
Buy
Maintained
$11.00
+166.3%
10/13/2026
Anderson Schock
B. Riley Securities
Buy
Reiterated
$12.00
+190.6%
08/05/2026
Unknown Analyst
Roth MKM
Buy
Initiated
$8.00
+93.7%
06/24/2026
Andrew Brackmann
William Blair
Buy
Reiterated
-
-
05/12/2026
William Bonello
Craig-Hallum
Buy
Reiterated
$10.00
+142.1%
03/11/2026
Paul Knight
KeyBanc
Buy
Maintained
$10.00
+142.1%
03/11/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
16.63M
17.31M
19.94M
18.42M
Cost of goods sold
7.42M
7.10M
7.72M
7.58M
Cost of revenue
7.42M
7.10M
7.72M
7.58M
Research and development expenses
1.76M
1.55M
1.43M
2.41M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12.42M
12.07M
12.51M
12.83M
Operating expense
14.18M
13.62M
13.94M
15.24M
Total operating expenses
21.61M
20.72M
21.66M
22.82M
Operating income
-4.98M
-3.41M
-1.72M
-4.41M
Other non operating income
-
-132.00K
153.00K
181.00K
EBT including unusual items
-4.66M
-3.93M
-3.20M
-6.34M
EBT excluding unusual items
-6.26M
-4.81M
-2.77M
-5.43M
Income tax expense
13.00K
36.00K
-
-1.00K
Effective tax rate
-0.28%
-0.92%
-
0.02%
Other operating expenses
-
-
-
-
Net income
-4.67M
-3.97M
-3.20M
-6.34M
Net profit margin
-28.10%
-22.92%
-16.03%
-34.40%
Earnings per share
-0.27
-0.20
-0.11
-0.22
Interest and investment income
43.00K
-
-
-
Interest expense
-1.33M
-1.27M
-1.20M
-1.20M
Net interest expenses
-1.29M
-1.27M
-1.20M
-1.20M
Depreciation and amortization charges
-
-
-
-
EBITDA
-4.38M
-2.82M
-1.09M
-3.78M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps